All In Biotech

Drug Trial Radar · NCT07286006

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

372

Planned (sponsor's estimate)

Start

Jan 26, 2026

Primary completion

Mar 2030

Study completion Mar 2030

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Conditions

  • Graves' Disease

Interventions

  • IMVT-1402Drug

    Dose 1 for up to 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402Time frame: At Week 52

Locations

131 sites in 11 countries. Site status is shown where the registry gives one.

  • Site Number - 1561

    Phoenix, Arizona

  • Site Number - 1519

    Phoenix, Arizona

  • Site Number - 1530

    Tucson, Arizona

  • Site Number - 1510

    Concord, California

  • Site Number - 1587

    Huntington Beach, California

  • Site Number - 1554

    Los Angeles, California

  • Site Number - 1588

    Orange, California

  • Site Number - 1559

    San Francisco, California

  • Site Number - 1558

    Santa Clarita, California

  • Site Number - 1552

    Torrance, California

  • Site Number - 1533

    Aurora, Colorado

  • Site Number -1514

    Englewood, Colorado

  • Site Number - 1516

    Newark, Delaware

  • Site Number - 1567

    Washington D.C., District of Columbia

  • Site Number - 1556

    Clearwater, Florida

  • Site Number - 1522

    Doral, Florida

  • Site Number - 1523

    Hialeah, Florida

  • Site Number - 1581

    Jacksonville, Florida

  • Site Number - 1582

    Jacksonville, Florida

  • Site Number - 1505

    Miami, Florida

  • Site Number - 1564

    Miami, Florida

  • Site Number - 1591

    Miami, Florida

  • Site Number - 1590

    Ocoee, Florida

  • Site Number - 1508

    Orlando, Florida

  • Site Number - 1507

    Port Charlotte, Florida

  • Site Number - 1548

    West Palm Beach, Florida

  • Site Number - 1566

    Atlanta, Georgia

  • Site Number - 1526

    Columbus, Georgia

  • Site Number - 1579

    Macon, Georgia

  • Site Number - 1518

    Stockbridge, Georgia

  • Site Number - 1562

    Indianapolis, Indiana

  • Site Number - 1568

    Kansas City, Kansas

  • Site Number - 1534

    Topeka, Kansas

  • Site Number - 1571

    Bowling Green, Kentucky

  • Site Number - 1580

    Florence, Kentucky

  • Site Number - 1546

    Louisville, Kentucky

  • Site Number - 1589

    Metairie, Louisiana

  • Site Number - 1555

    New Orleans, Louisiana

  • Site Number - 1565

    Baltimore, Maryland

  • Site Number - 1557

    Boston, Massachusetts

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.